The Insurance Maze: Getting Your Migraine Treatment Approved

The System Is Not Built to Help You

Your doctor prescribed Emgality. You left the appointment feeling, for the first time in years, genuinely hopeful.

Then the pharmacy called. Insurance denied it.

If that sentence lands somewhere specific in your chest — you are not alone. A joint survey of more than 1,900 migraine patients found that 64% had been through prior authorization battles, and nearly 80% said the interference made their attacks more frequent, more severe, or both.^[1] In that same report, 74% said the obstruction worsened their disease over time — not just their mood, their actual disease.^[1]

These are not administrative inconveniences. They are medical harms delivered in envelope form.

But here is what insurance companies count on: almost nobody fights back. Research shows up to 50% of denied claims can be overturned on appeal — yet fewer than 1% of patients ever challenge a denial.^[2] That gap between what is possible and what people actually do is the most exploited space in American healthcare.

This article is your map through that space. Every obstacle named. Every lever you have the legal right to pull.

Five Tactics the Insurance Industry Uses to Wear You Down

Before you can fight, you need to know what you are fighting.

Prior Authorization (PA). Your insurer requires advance approval before covering a medication. Your doctor prescribes; the insurer reviews; and too often, the insurer denies. Nearly half of migraine patients wait more than a week for a decision.^[1] Physicians now spend an average of 13 hours every single week navigating PA paperwork — and 93% of them say it causes measurable delays in patient care.^[3] When your doctor’s staff is buried in forms, that is time not spent treating you.

Step Therapy — “Fail First.” You cannot have the medication your doctor chose until you have first tried and documented failure with cheaper alternatives. For CGRP inhibitors like Aimovig or Emgality, this typically means failing two older drugs — usually topiramate, amitriptyline, or propranolol — before the insurer will budge. Here is the problem: the American Headache Society’s 2024 position statement explicitly recognizes CGRP-targeting therapies as a first-line treatment option.^[4] The insurer’s requirement is not evidence-based. It is cost-containment dressed as medicine.

Non-Medical Switching. Midyear, your insurer quietly pulls your stable medication from its formulary — usually because a pharmaceutical rebate deal shifted the economics — and substitutes a different drug. You were not consulted. Your doctor was not consulted. One patient described it this way: “The condition was stabilized. And then the insurance company drove me to a drug that’s less expensive. The switch prioritized their profit over my health.”^[1]

Combination Therapy Denial. Evidence supports using Botox alongside CGRP monoclonal antibodies in hard-to-treat chronic migraine. The two drugs work on completely different mechanisms and non-overlapping targets.^[5] Many insurers deny both simultaneously, calling the combination “experimental” — despite published clinical evidence that says otherwise. We’ll come back to exactly how to fight this specific denial near the end of this article.

AI-Generated Batch Denials. A 2025 American Medical Association report found that some insurers now deploy AI systems that produce automatic, batch denials with little or no human review — some generating denial rates up to 16 times higher than human reviewers.^[3] The AMA President called it bluntly: medical decisions must be made by physicians and their patients, “without interference from unregulated and unsupervised AI technology.”^[3] A boilerplate machine denial is far easier to overturn on appeal than a carefully reasoned medical judgment.

Your Most Powerful Weapon: The Migraine Diary

Before you call the insurer. Before you write an appeal letter. Before anything else — you need documentation.

A detailed migraine diary is the single most important asset in any insurance dispute. Insurance reviewers are trained to look for evidence of medical necessity. Your diary provides it in a format they cannot dismiss.

Track every attack: date, time, duration, pain severity on a 1–10 scale, symptoms present (nausea, aura, light sensitivity, cognitive fog), impact on daily function (missed work, unable to drive, bedridden), and medications taken along with how well they worked. Do this consistently for 30 to 90 days before any appeal.

This record serves three purposes. It establishes the frequency and severity of your condition in objective, dated terms. It documents failure of previous medications — exactly what step therapy protocols require as proof. And in the event of an external independent review, it becomes your most compelling evidence of functional impairment.^[6]

The Migraine Companion app was built for this. Every attack you log builds the medical record that protects your access to treatment.

How Prior Authorization Actually Works — And Where It Breaks

PAs fail for preventable reasons. The most common cause is not a malicious denial — it is incomplete paperwork. The prescriber’s office submitted a vague diagnosis code, skipped a required question, or answered “no” because they could not find the specific answer in your chart.^[7]

Ask your doctor’s office to confirm that the following appear in your clinical notes — because the insurer will ask for them:

A cumulative medication list: every migraine drug you have tried, with the dose, how long you took it, and the specific reason you stopped — “ineffective after 3 months at maximum dose” carries far more weight than “didn’t work.” A precise ICD-10 diagnosis code — not a catch-all like “headache disorder” but the exact code for your migraine subtype. Your disability score: insurers like Cigna explicitly require documented “at least moderate disability” — a MIDAS score of 11 or higher, or a HIT-6 score above 50 — before approving CGRP therapies.^[8] And confirmation that Medication Overuse Headache has been ruled out, which many plans ask about specifically for CGRP monoclonal antibodies.^[7]

If your situation is urgent — if your doctor can certify that waiting would seriously jeopardize your health — you have the right to request an expedited review. Expedited reviews require a decision within 24 hours.^[9] Most patients do not know this. Most never ask.

The Appeal Ladder: How to Climb It

A denial is not a verdict. It is the opening bid in a negotiation you are legally entitled to pursue.

Rung 1: Read the denial letter carefully. It must state the specific reason for denial, the policy used to justify it, your appeal rights, and the deadline. Miss the deadline — typically 65 to 180 days — and you forfeit your rights entirely.^[9]

Rung 2: Get a Letter of Medical Necessity. Your neurologist writes a letter explaining, in clinical terms, why this specific medication is medically necessary for you — not for migraine patients generally, but for your history, your failed treatments, your documented disability. The letter should cite the 2024 AHS position statement on CGRP therapies^[4] and name every alternative tried and failed, with documented reasons. The stronger and more specific the letter, the harder it is to deny.^[6]

Rung 3: Request a Peer-to-Peer Review. This is the most underused and most often decisive tool in the appeal process. Your physician calls the insurance company’s medical reviewer directly. Doctor to doctor. They cannot dismiss clinical arguments from another clinician speaking in specific medical terms the same way they dismiss a written form.^[6] Push your doctor’s office to request one — it often takes a single phone call to change the outcome.

Rung 4: Escalate inside the company. If the first internal appeal is denied, resubmit. Each resubmission moves the case to a higher-level reviewer. Keep records of every interaction: date, time, representative’s name, reference number. Insurers count on exhaustion — persistent, documented patients are their least favorite cases.

Rung 5: Demand an External Independent Review. If internal appeals fail, you have the legal right in most states to have your case reviewed by an independent third-party organization — one with no financial relationship with your insurer. External reviewers overturn a substantial proportion of migraine-related denials, because the clinical evidence for CGRP treatments is strong.^[2]

Bridge Programs: You Don’t Have to Wait to Feel Better

You should not suffer for months while an appeal crawls through the system. Manufacturer patient assistance programs exist precisely to fill this gap. As of 2025, active programs include:^[10]

• Aimovig (Amgen) — The Aimovig Ally™ Bridge-to-Coverage program provides free medication for up to 12 doses while PA is being pursued. Once coverage is established, commercially insured patients pay as little as $5/month (max benefit $3,500/year).
• Emgality (Lilly) — Eligible commercially insured patients may pay as little as $0 for up to 12 months via the Emgality Savings Card.
• Ajovy (Teva) — Commercially insured patients may pay $0 via a manufacturer savings coupon.
• Nurtec ODT (rimegepant) — Eligible commercially insured patients pay as little as $0/month via the Nurtec ODT Patient Savings Program.
• Qulipta (atogepant) — Savings card available for commercially insured patients.
• Botox (AbbVie) — Savings program created to help commercially insured patients with out-of-pocket costs not covered by insurance.

The Legal Landscape: Rights You Already Have

Thirty-one states have passed step therapy exception laws requiring insurers to grant exceptions under specific circumstances.^[12] The law typically requires your insurer to bypass step therapy if: you have already tried and failed the required drug; the required drug is contraindicated for your medical situation; delaying treatment would cause irreversible harm; or the required drug would prevent you from performing daily activities or doing your job.

If your state has one of these laws, cite it by name in your appeal. Your insurer’s legal team knows about it, even if the representative you spoke to does not.

If you have employer-sponsored insurance through a self-insured plan, state laws may not apply to you — because federal ERISA law largely preempts state regulation of these plans.^[12] The Safe Step Act (H.R. 2630 / S. 652) — backed by 233 House cosponsors and 45 Senate cosponsors as of 2024 — would extend these protections to the roughly 100 million Americans currently left without them.^[13] Advocating for this legislation is not abstract politics. For many people, it is the direct difference between access and denial.

The Combination Therapy Battle

One of the most infuriating denials is the refusal to cover Botox alongside a CGRP monoclonal antibody simultaneously. Insurers typically call the combination “experimental” or “duplicative.” Both arguments are clinically unsupported.

Botox acts on peripheral trigeminal nerve terminals and sensory neuropeptide release. CGRP monoclonal antibodies work systemically by blocking the CGRP protein in circulation. These are non-overlapping mechanisms targeting different parts of the same pathological cascade.^[5] For patients with hard-to-control chronic migraine, addressing multiple pathways simultaneously is not a luxury — it is sound pharmacology. Published evidence confirms better outcomes with combination therapy for patients who have not achieved adequate control with either agent alone.^[5]

If you are denied combination therapy, the appeal strategy is the same as above — but with one critical addition. Ask your neurologist to document the specific, individualized medical rationale for needing both agents: your history, your failed monotherapy trials, your documented response to each drug alone. Generic statements do not win these appeals. Specificity does.